Loading…
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.7B | $489M | $247M | $350M | 16.3% | 30.7% | -40.9% |
| 2024 | $2.1B | $424M | $418M | $296M | 34.5% | 22.1% | 102.8% |
| 2023 | $1.7B | $324M | $206M | $37M | 28.2% | 30.0% | 4384.8% |
| 2022 | $1.3B | $109M | $5M | $-38M | 1.0% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,305.30 | 1,697.10 | 2,071.60 | 2,708.10 |
| Operating Revenue | - | 1,305.30 | 1,697.10 | 2,071.60 | 2,708.10 |
| Cost Of Revenue | - | 499.70 | 537.20 | 625.90 | 768.20 |
| Gross Profit | - | 805.60 | 1,159.90 | 1,445.70 | 1,939.90 |
| Operating Expense | - | 768 | 939.80 | 1,136.80 | 1,466.10 |
| Research And Development | - | 180.20 | 205 | 219.60 | 301.10 |
| Selling General And Administration | - | 587.80 | 734.80 | 917.20 | 1,165 |
| Total Expenses | - | 1,267.70 | 1,477 | 1,762.70 | 2,234.30 |
| Operating Income | - | 37.60 | 220.10 | 308.90 | 473.80 |
| Total Operating Income As Reported | - | 37.60 | 220.10 | 308.90 | 473.80 |
| EBITDA | - | 109 | 323.70 | 423.70 | 489.30 |
| Normalized EBITDA | - | 109 | 323.70 | 423.70 | 600.70 |
| EBIT | - | 45.80 | 250.90 | 342.90 | 398.90 |
| Interest Income | - | 9.30 | 28.60 | 39.50 | 34.70 |
| Interest Expense | - | 36 | 36.20 | 42.70 | 59.40 |
| Net Interest Income | - | -26.70 | -7.60 | -3.20 | -24.70 |
| Other Non Operating Income Expenses | - | -1.10 | 2.20 | -5.50 | 1.80 |
| Other Income Expense | - | -1.10 | 2.20 | -5.50 | -109.60 |
| Interest Income Non Operating | - | 9.30 | 28.60 | 39.50 | 34.70 |
| Interest Expense Non Operating | - | 36 | 36.20 | 42.70 | 59.40 |
| Net Non Operating Interest Income Expense | - | -26.70 | -7.60 | -3.20 | -24.70 |
| Pretax Income | - | 9.80 | 214.70 | 300.20 | 339.50 |
| Tax Provision | - | 5.20 | 8.30 | -118.10 | 92.40 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | -30.32 |
| Net Income Continuous Operations | - | 4.60 | 206.30 | 418.30 | 247.10 |
| Net Income From Continuing And Discontinued Operation | - | 4.60 | 206.30 | 418.30 | 247.10 |
| Net Income From Continuing Operation Net Minority Interest | - | 4.60 | 206.30 | 418.30 | 247.10 |
| Net Income | - | 4.60 | 206.30 | 418.30 | 247.10 |
| Net Income Common Stockholders | - | 4.60 | 206.30 | 418.30 | 247.10 |
| Net Income Including Noncontrolling Interests | - | 4.60 | 206.30 | 418.30 | 247.10 |
| Normalized Income | - | 4.60 | 206.30 | 418.30 | 328.18 |
| Diluted NI Availto Com Stockholders | - | 4.60 | 216.80 | 427.40 | 250.10 |
| Basic Average Shares | - | 69.38 | 69.75 | 70.08 | 70.35 |
| Diluted Average Shares | - | 69.91 | 73.63 | 73.89 | 71.89 |
| Reconciled Depreciation | - | 63.20 | 72.80 | 80.80 | 90.40 |
| Reconciled Cost Of Revenue | - | 499.70 | 537.20 | 625.90 | 768.20 |
| Total Unusual Items | - | 0 | 0 | 0 | -111.40 |
| Total Unusual Items Excluding Goodwill | - | 0 | 0 | 0 | -111.40 |
| Special Income Charges | - | 0 | 0 | 0 | -123.90 |
| Other Special Charges | 42.40 | - | - | - | 123.90 |
| Gain On Sale Of Security | - | - | - | - | 12.50 |
| Total Other Finance Cost | 3.50 | 4.30 | - | - | - |
| Average Dilution Earnings | - | - | 10.40 | 9.10 | 3 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Insulet Corporationthis co. | PODD | $10.1B | 41.04↑ premium | 6.69 | 16.3% | 21.20 |
| Incyte Corporation | INCY | $20.2B | 15.72 | 3.91 | 24.9% | 9.75 |
| Viatris Inc. | VTRS | $18.5B | - | 1.26 | -23.9% | - |
| Zimmer Biomet Holdings, Inc. | ZBH | $16.8B | 23.79 | 1.32 | 5.6% | 10.69 |
| Solventum Corporation | SOLV | $14.3B | 9.17 |
| - |
| - |
| - |
| - |
| - |
| 2.83 |
| 30.8% |
| 7.23 |
| DaVita Inc. | DVA | $12.3B | 16.52 | -18.94 | -114.7% | 9.29 |
| The Cooper Companies, Inc. | COO | $12.1B | 32.28 | 1.47 | 4.6% | 13.89 |
| Align Technology, Inc. | ALGN | $12.1B | 29.37 | 2.98 | 10.1% | 13.46 |
| Universal Health Services, Inc. | UHS | $8.6B | 5.80 | 1.19 | 20.5% | 4.98 |
| Peer Median | - | 16.52 | 1.39 | 7.8% | 9.75 | |